CAPR Capricor Therapeutics, Inc.
$6.10▲ +6.27%
Healthcare
Other
After hours
$6.08▼ -0.31%
Oct 27, 5:43 PM ET
Volume 3.46M
Avg Volume (10D) 2.36M
Key Metrics & Fundamentals
Market Cap
$354.65M
P/E Ratio
–
Div Yield
0.00%
52W Range
2.96 - 40.37
% vs 50 MA
-24.78%
% vs 200 MA
-70.88%
RSI-14
37.2
MACD Histogram
-0.1000
Beta (1Y vs SPY)
0.98
Free Cash Flow
-$37.39M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$44.60M
COGS
–
Operating Exp
$42.95M
Operating Income
-$42.95M
EBIT
-$42.95M
Pretax Income
-$40.73M
Net Income
-$40.73M
EPS (Diluted)
-0.70
Price & Volume History
Loading chart…
Recent News
CAPR Stock on Track For Worst Month Since July AdCom Vote On Deramiocel As November FDA Decision Nears
Stocktwits · Oct 21, 2026 3:52 PM ET
CAPR Stock Rises Nearly 5% As Capricor Presents Heart Data For Deramiocel Ahead Of November FDA Decision
Stocktwits · Oct 7, 2026 7:30 PM ET
Capricor Highlights Two-Year Deramiocel Data as FDA Decision Nears
MarketBeat · Oct 7, 2026 7:02 PM ET
Capricor’s DMD Therapy Shows 76% Slower Upper-Limb Decline — This Analyst Expects A Complete Response Letter In November
Stocktwits · Oct 5, 2026 11:59 AM ET
Capricor Therapeutics Presents Positive HOPE-3 Open-Label Extension Data on Upper Limb Function in Duchenne Muscular Dystrophy at 2026 World Muscle Society Congress
GlobeNewswire · Oct 5, 2026 9:00 AM ET
CAPR Stock Clocks Best Day In Over A Month As 24-Month Duchenne Data Airs At Medical Conference In Japan
Stocktwits · Sep 30, 2026 8:02 PM ET
Top Premarket Gainers
MT Newswires · Sep 30, 2026 7:15 AM ET
Why Did CAPR Stock Jump 20% After-Hours Today?
Stocktwits · Sep 29, 2026 9:24 PM ET
Capricor Therapeutics (CAPR) Stock Gets Fair Value Boost After Deramiocel Analyst Revisions
Simply Wall St. · Sep 23, 2026 9:19 AM ET
Capricor Therapeutics to Present HOPE-3 and HOPE-3 Open-Label Extension Data at 2026 World Muscle Society Congress
GlobeNewswire · Sep 17, 2026 8:30 AM ET
Financial Overview - Income Statement
Quarterly
Dec 2024
See CAPR's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.